

Client: LA VITALITY 20783 Patient: NOACK, ADAM

9301 Wilshire Blvd Phone: ( ) - DOB. 10/04/1995 Age:28 Sex: M
404 Address 1: Fasting: Y

404 Address 1: BEVERLY HILLS, CA 90210 Address 2:

Phys: KAWESCH, GARY (561) 425-6354 City: State: Zip: Page:1

 Acc#
 004440165
 Coll. Date: 12/15/23
 Recv. Date: 12/18/23
 Print Date: 12/19/23

 Chart#
 Coll. Time: 09:16 AM
 Recv. Time:10:23 AM
 Print Time: 09:27

 First reported on:
 12/16/23 08:31
 Final report date:
 12/19/23

Report Status: FINAL

**Test Name** 

********OUT OF	RANGE SUMMARY*****	*******	*****	
		reported: 12/16/23 08:14		
Glucose	106 н	70 - 99	mg/dL	*1
Potassium	5.3 н	3.5 - 5.2	mmol/L	*1
		reported: 12/16/	23 11:08	
Sex Horm Binding Glob, Serum	57.2 H	16.5 - 55.9	nmol/L	*1

Results

Units

ng/mL

\*1

Reference Range

30.0 - 100.0

reported: 12/16/23 08:14

Vitamin D, 25-Hydroxy 27.0 L

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

- 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
- 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

\*\*\*\*\*

## reported: 12/16/23 08:14 CBC With Differential/Platelet

WBC	5.3	3.4 - 10.8	x10E3/uL	*1
RBC	5.57	4.14 - 5.80	x10E6/uL	*1
Hemoglobin	16.5	13.0 - 17.7	g/dL	*1
Hematocrit	49.2	37.5 - 51.0	%	*I
MCV	88	79 - 97	fL	*1
MCH	29.6	26.6 - 33.0	pg	*1
MCHC	33.5	31.5 - 35.7	g/dL	*I
RDW	11.8	11.6 - 15.4	%	*I
Platelets	230	150 - 450	x10E3/uL	*I
Neutrophils	57	Not Estab.	%	*I
Lymphs	29	Not Estab.	%	*I
Monocytes	11	Not Estab.	%	*I
Eos	2	Not Estab.	%	*I
Basos	1	Not Estab.	%	*1
Neutrophils (Absolute)	3.1	1.4 - 7.0	x10E3/uL	*1

(Continued on Next Page)



Client: LA VITALITY 20783 Patient: NOACK, ADAM

9301 Wilshire Blvd Phone: DOB. 10/04/1995 Age:28 Sex: M ( ) -Fasting: Y 404 Address 1:

BEVERLY HILLS, CA 90210 Address 2:

Phys: KAWESCH, GARY (561) 425-6354 City: Page:2 State: Zip:

Acc# 004440165 Coll. Date: 12/15/23 Recv. Date: 12/18/23 Print Date: 12/19/23 Chart# Coll. Time: 09:16 AM Recv. Time:10:23 AM Print Time: 09:27

First reported on: 12/16/23 08:31 Final report date: 12/19/23

Test Name		Results	Reference Range	Units	
******* (Continued)				·!	
Lymphs (Absolute)		1 5	0.7.2.1	**10E2/vI	:
Lymphs (Absolute)		1.5 0.6	0.7 - 3.1	x10E3/uL	
Monocytes(Absolute)			0.1 - 0.9	x10E3/uL	
Eos (Absolute)		0.1	0.0 - 0.4	x10E3/uL	
Baso (Absolute)		0.0	0.0 - 0.2	x10E3/uL	
Immature Granulocytes		0	Not Estab.	%	
Immature Grans (Abs)		0.0	0.0 - 0.1	x10E3/uL	
			reported: 12/16/2	23 08:14	
Comp. Metabolic Panel (14)		404		/ 1=	
Glucose		106 н	70 - 99	mg/dL	
BUN		19	6 - 20	mg/dL	
Creatinine		1.21	0.76 - 1.27	mg/dL	
eGFR		84	>59	mL/min/1.7	
BUN/Creatinine Ratio		16	9 - 20		
Sodium		142	134 - 144	mmol/L	
Potassium		5.3 H	3.5 - 5.2	mmol/L	
Chloride		101	96 - 106	mmol/L	
Carbon Dioxide, Total		25	20 - 29	mmol/L	
Calcium		9.9	8.7 - 10.2	mg/dL	
Protein, Total		7.4	6.0 - 8.5	g/dL	
Albumin		5.0	4.3 - 5.2	g/dL	
Globulin, Total		2.4	1.5 - 4.5	g/dL	
A/G Ratio		2.1	1.2 - 2.2		
Bilirubin, Total		0.4	0.0 - 1.2	mg/dL	
Alkaline Phosphatase		64	44 - 121	IU/L	
AST (SGOT)		21	0 - 40	IU/L	
ALT (SGPT)		25	0 - 44	IU/L	
			reported: 12/16/2	23 08:14	
Lipid Panel		105			
Cholesterol, Total		195	100 - 199	mg/dL	
Triglycerides		59	0 - 149	mg/dL	
HDL Cholesterol		88	>39	mg/dL	
VLDL Cholesterol Cal		11	5 - 40	mg/dL	
LDL Chol Calc (NIH)		96	0 - 99	mg/dL	
			reported: 12/16/2	23 08:14	
Vitamin B12		578	232 - 1245	pg/mL	
			reported: 12/16/2	23 08:14	
Prostate Specific Ag	(Continued on Next Page)	0.4	0.0 - 4.0	ng/mL	



Client: LA VITALITY 20783 Patient: NOACK, ADAM 9301 Wilshire Blvd Phone: ( ) -DOB. 10/04/1995 Age:28 Sex: M 404 Address 1: Fasting: Y BEVERLY HILLS, CA 90210 Address 2: Phys: KAWESCH, GARY (561) 425-6354 City: State: Zip: Page:3 Acc# 004440165 Coll. Date: 12/15/23 Recv. Date: 12/18/23 Print Date: 12/19/23 Chart# Coll. Time: 09:16 AM Recv. Time:10:23 AM Print Time: 09:27 First reported on: 12/16/23 08:31 Final report date: 12/19/23 Report Status: FINAL **Test Name** Results Units Reference Range \*\*\*\*\*\* (Continued) Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. reported: 12/16/23 08:14 **TSH** 0.875 \*1 0.450 - 4.500uIU/mL reported: 12/16/23 08:14 **FSH** 3.9 \*1 1.5 - 12.4 mIU/mL reported: 12/16/23 08:14 **Luteinizing Hormone(LH)** LH 4.9 \*1 1.7 - 8.6mIU/mL reported: 12/16/23 08:14 Estradiol 25.8 7.6 - 42.6\*1 pg/mL Roche ECLIA methodology reported: 12/16/23 11:08 **Testosterone Free, Profile I** 795 Testosterone 264 - 916 \*1 ng/dL Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. 57.2 H Sex Horm Binding Glob, Serum \*1 16.5 - 55.9 nmol/L Testost., Free, Calc 117.4 47.7 - 173.9 \*1 pg/mL reported: 12/16/23 19:06 \*1 Hemoglobin A1c 5.4 4.8 - 5.6 Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 reported: 12/19/23 08:10 IGF-1 Insulin-Like Growth Factor I 222 \*1 101 - 307 ng/mL (Continued on Next Page)



Client: LA VITALITY 20783 Patient: NOACK, ADAM

BEVERLY HILLS, CA 90210 Address 2:

Phys: KAWESCH, GARY (561) 425-6354 City: State: Zip: Page:4

 Acc# 004440165
 Coll. Date: 12/15/23
 Recv. Date: 12/18/23
 Print Date: 12/19/23

 Chart#
 Coll. Time: 09:16 AM
 Recv. Time:10:23 AM
 Print Time: 09:27

 First reported on:
 12/16/23 08:31
 Final report date:
 12/19/23

Report Status: FINAL

Test Name Results Reference Range Units

## \*\*\*\*\*\* (Continued)

Vitamin D, 25-Hydroxy

reported: 12/16/23 08:14 27.0 L 30.0 - 100.0 ng/mL

\*1

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

- 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
- 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

Director: Alan Sara, M.D

COMMENTS: Fasting,

END OF REPORT \_

\*1) Unless otherwise noted, Tests Performed at: LABCORP, 5610 WEST LA SALLE STREET, TAMPA, FL 33607

